[Update in hospital internal medicine (2007): a selection].
This paper summarizes several important studies published during the previous year that have an impact on the practice of inpatient internal medicine, because they either modify or reinforce current practices. The selected domains include the treatment of thrombo-embolic disease, the role of implantable defibrillators in left cardiac failure, the management of cerebro-vascular disease, of community-acquired pneumonia, and of type 2 diabetes, as well as the prevention of spontaneous bacterial peritonitis in cirrhosis and of osteoporosis fractures. Some data stimulating our reflection on the integration of medical education in health care centres and on the validity of some scientific publications are also presented.
Nendaz
Mathieu
M
Service de médecine interne générale, Département de médecine interne, HUG, Genève. mathieu.nendaz@hcuge.ch
Perrier
Arnaud
A
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000188:drug therapy; D003327:Coronary Disease / Q000000981:diagnostic imaging; D000069604:Dabigatran; D017147:Defibrillators, Implantable; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D050723:Fractures, Bone / Q000517:prevention & control; D006333:Heart Failure / Q000601:surgery; D006338:Heart Neoplasms / Q000209:etiology; D006622:Hip Prosthesis; D006748:Hospital Departments; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007388:Internal Medicine / Q000193:education / Q000592:standards; D008103:Liver Cirrhosis / Q000150:complications; D009844:Oligosaccharides / Q000627:therapeutic use; D010024:Osteoporosis / Q000150:complications; D010538:Peritonitis / Q000517:prevention & control; D018410:Pneumonia, Bacterial / Q000188:drug therapy; D011655:Pulmonary Embolism / Q000188:drug therapy; D011725:Pyridines / Q000627:therapeutic use; D011787:Quality of Health Care; D012307:Risk Factors; D020521:Stroke / Q000517:prevention & control; D013663:Teaching / Q000379:methods; D014057:Tomography, X-Ray Computed / Q000379:methods; D020246:Venous Thrombosis / Q000188:drug therapy / Q000517:prevention & control
D000900:Anti-Bacterial Agents; D000925:Anticoagulants; D001562:Benzimidazoles; D050071:Bone Density Conservation Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D009844:Oligosaccharides; D011725:Pyridines; C479958:idraparinux; D000069604:Dabigatran